MAO-A, MAO-B and MAO-A/B inhibitors have all been shown to reduce cytokine expression in CNS-associated disease models (Bielecka et al., 2010; Fernandez et al., 2011; Panarsky et al., 2012; Trudler et al., 2014; Liu et al., 2020; Tomaz et al., 2020) and non-CNS-associated disease models that examined either whole blood, bone stromal cells, periodontal tissues, lung tissues or bone marrow-derived macrophages samples (Lin et al., 2000; Ekuni et al., 2009; Chaaya et al., 2011; Cui et al., 2017; Wu et al., 2017; Cui et al., 2020; Sanchez-Rodriguez et al., 2021). Here, MAOA is linked to glycogen storage disease VI.